Department of Pharmacology and Therapeutics, Makerere University College of Health Sciences, Kampala, Uganda.
Clinical Epidemiology Unit, Makerere University College of Health Sciences, Kampala, Uganda.
Malar J. 2021 Apr 9;20(1):178. doi: 10.1186/s12936-021-03712-3.
Prompt detection and appropriate treatment of malaria prevents severe disease and death. The quality of care for adult malaria in-patients is not well documented in sub-Saharan Africa, particularly in Uganda. The study sought to describe the patterns of malaria diagnosis and treatment among adult in-patients admitted to the medical and gynaecological wards of Uganda's 1790-bed Mulago National Referral Hospital from December 2013 to April 2014.
A prospective cohort of 762 consented in-patients aged ≥ 18 years was assembled. Proportions of in-patients who received preadmission and in-hospital anti-malarials, missed Day 1 dosing of hospital-initiated anti-malarials and/or had malaria microscopy done were determined. Multivariable logistic regression was used to identify risk-factors for missed Day 1 dosing of anti-malarials.
One in five (19%, 146/762) in-patients had an admission or discharge malaria diagnosis or both; with median age of 29 years (IQR, 22-42 years). Microscopy was requested in 77% (108/141) of in-patients with an admission malaria diagnosis; results were available for 46% (50/108), of whom 42% (21/50) tested positive for Plasmodium falciparum malaria parasitaemia. Only 13% (11/83) of in-patients who received in-hospital injectable artesunate (AS) or quinine (Q) received follow-up oral artemether-lumefantrine (AL); 2 of 18 severe malaria cases received follow-up oral AL. Injectable AS only (47%, 47/100) was the most frequent hospital-initiated anti-malarial treatment followed by injectable Q only (23%, 23/100) amongst in-patients who received in-hospital anti-malarials. A quarter (25%, 25/100; 95% CI: 17-35%) of in-patients missed Day 1 dosing of hospital-initiated anti-malarials. Each additional admission diagnosis was more than two-fold likely to increase the odds of missed Day 1 dosing of in-hospital anti-malarials (aOR = 2.6, 95% CI: 1.52-4.56; P-value = 0.001).
Half the malaria microscopy results were not available; yet, the rate of testing was high. The majority of in-patients initiated on injectable AS or Q did not receive the recommended follow-up oral AL. One in four in-patients delayed to initiate hospital anti-malarials by at least one calendar day. The hospital should encourage prompt availability of malaria test-results to promote the timely initiation and completion of anti-malarial treatment, thereby improving the quality of care for hospitalized malaria patients in Uganda.
及时发现和适当治疗疟疾可预防重症疾病和死亡。在撒哈拉以南非洲,特别是在乌干达,成人疟疾住院患者的护理质量尚未得到很好的记录。本研究旨在描述 2013 年 12 月至 2014 年 4 月期间乌干达 1790 张病床的穆拉戈国家转诊医院内科和妇科病房收治的成年住院患者中疟疾的诊断和治疗模式。
我们组建了一个包含 762 名年龄≥18 岁并同意参加的住院患者前瞻性队列。确定了接受入院前和住院期间抗疟药物、漏服住院起始抗疟药物首日剂量以及进行疟疾显微镜检查的住院患者的比例。采用多变量逻辑回归来确定漏服首日抗疟药物的风险因素。
五分之一(19%,146/762)的住院患者有入院或出院疟疾诊断或两者兼有;中位年龄为 29 岁(IQR,22-42 岁)。在有入院疟疾诊断的 141 名住院患者中,77%(108/141)要求进行显微镜检查;其中 46%(50/108)的结果可用,其中 42%(21/50)检测出恶性疟原虫疟原虫血症阳性。仅 13%(11/83)接受院内注射用青蒿琥酯(AS)或奎宁(Q)的住院患者接受了后续口服青蒿素-哌喹(AL)治疗;18 例严重疟疾病例中有 2 例接受了后续口服青蒿素-哌喹治疗。在接受院内抗疟药物治疗的住院患者中,最常见的治疗方法是注射用 AS(47%,47/100),其次是注射用 Q(23%,23/100)。接受院内抗疟药物治疗的住院患者中,有四分之一(25%,25/100;95%CI:17-35%)漏服了首日剂量的医院起始抗疟药物。每增加一个入院诊断,漏服首日剂量的院内抗疟药物的可能性就会增加两倍以上(aOR=2.6,95%CI:1.52-4.56;P 值=0.001)。
一半的疟疾显微镜检查结果无法获得;然而,检测率很高。大多数接受注射用 AS 或 Q 治疗的住院患者未接受推荐的后续口服青蒿素-哌喹治疗。四分之一(25%,25/100)的住院患者至少延迟一天开始接受医院抗疟药物治疗。医院应鼓励及时提供疟疾检测结果,以促进及时启动和完成抗疟治疗,从而提高乌干达住院疟疾患者的护理质量。